Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0917801 (insomnia)
 10,606 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Information is available on aripiprazole as a treatment for borderline personality disorder (BPD), but no data have yet been presented concerning the use of this drug as an adjunctive treatment for drug-resistant BPD patients. This study investigates aripiprazole augmentation of ongoing sertraline therapy in drug-resistant BPD patients. Twenty-one outpatients with a DSM-IV-TR diagnosis of BPD who did not respond to sertraline, 100-200 mg/day for 12 weeks, were treated for 12 weeks with the addition of aripiprazole, 10-15 mg/day. Patients were assessed at baseline, week 4, and week 12 with the Clinical Global Impression Scale - Severity item (CGI-S), the Brief Psychiatric Rating Scale (BPRS), the Hamilton scales for depression and anxiety (HAM-D, HAM-A), the Social Occupational Functioning Assessment Scale (SOFAS) for social functioning, the Borderline Personality Disorder Severity Index (BPDSI), and the Barratt Impulsiveness Scale (BIS-11). Adverse effects were evaluated using the Dosage Record and Treatment Emergent Symptom Scale (DOTES). Sixteen patients completed the study. Five patients (23.8%) dropped out due to anxiety/insomnia or non-compliance. Nine patients (56.3%) were responders. Analysis of variance revealed significant changes in the following measures: CGI-S, BPRS, BPDSI total score, BPDSI "impulsivity" and "dissociation/paranoid ideation" items, and BIS-11. Adverse effects were mild headache, insomnia, and anxiety. Aripiprazole is an efficacious and well-tolerated add-on treatment for sertraline-resistant BPD patients. It acts on impulsive and psychotic-like symptoms.
 ...
PMID:Efficacy and tolerability of aripiprazole augmentation in sertraline-resistant patients with borderline personality disorder. 1884 60

Sleep disturbance is identified as a prominent concern in cancer patients with detrimental effect on health outcome, which accompanies a decline in functional status, reduces quality of life, and even accelerates deterioration of disease. Therefore, in order to design safe and effective therapy, and improve the quality of life in cancer patients, it is necessary to seek the optimal measures of sleep quality evaluation, which include the objective assessments (e.g., polysomnography [PSG], the bispectral index [BIS], actigraphy) and subjective assessments (e.g., Pittsburgh Sleep Quality Index [PSQI], Insomnia Severity Index [ISI], Epworth Sleepiness Scale [ESS], Consensus Sleep Diary [CSD]) and understand the status of sleep quality in cancer patients, especially patients with cancers in the breast, lung, head and neck, ovaries, and uterus. This review summarizes the common methods used to measure sleep quality and compares the sensitivity, specificity, and practicability of these methods. In addition, the status of sleep disturbance in patients with cancer is analyzed.
 ...
PMID:Measurements and status of sleep quality in patients with cancers. 2905 28